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Extended summary:  
Humans vary substantially in their willingness to take risks. Though risk tolerance has been 
one of the most studied traits in social science genetics, few genetic variants have so far been 
found to robustly associate with it or with risky behaviors. In a combined sample of over one 
million individuals, we conducted genome-wide association studies (GWAS) of general risk 
tolerance, adventurousness, and risky behaviors in the driving, drinking, smoking, and sexual 
domains. (In a GWAS, a trait of interest is regressed on millions of genetic variants and 
stringent multiple testing corrections are applied to find variants that are associated with the 
trait.) Our GWAS identified 611 independent regions of the genome associated with one of 
our studied traits, including 124 associated with general risk tolerance.  
We report evidence of substantial shared genetic influences across general risk tolerance and 
risky behaviors: 72 of the 124 general risk tolerance regions contain a variant associated with 
at least one of the risky behaviors, and general risk tolerance is moderately to strongly 
genetically correlated (!"̂$! ~ 0.25 to 0.50) with a range of risky behaviors. (The genetic 
correlation between two traits measures the extent to which the genetic components of the two 
traits are correlated.) Our results suggest the existence of a genetically-influenced ‘general 
factor of risk tolerance’ that captures a general tendency to take risks across domains of 
behavior. In addition, we constructed ‘polygenic scores’ that partially predict individuals’ risk 
tolerance based on their genomes; such scores predict a suite of risky behaviors and account 
for up to ~1.6% of the variation in risk tolerance. 
Bioinformatics analyses point to the involvement of specific brain regions that have previously 
been identified in neuroscientific studies on decision-making, notably the prefrontal cortex, 
basal ganglia, and midbrain, thereby providing convergent evidence with that from 
neuroeconomics. We report evidence that the neurochemicals glutamate (which mediates 
communication across neurons) and GABA (which hinders communication) contribute to 
variation in risk tolerance across individuals. We find no evidence that genes previously 
reported to be associated with risk tolerance (such as genes related to the neurochemicals 
dopamine and serotonin) are actually associated with risk tolerance.  
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Abstract:  
Humans vary substantially in their willingness to take risks. In a combined sample of over one 
million individuals, we conducted genome-wide association studies (GWAS) of general risk 
tolerance, adventurousness, and risky behaviors in the driving, drinking, smoking, and sexual 
domains. We identified 611 approximately independent genetic loci associated with at least one of 
our phenotypes, including 124 with general risk tolerance. We report evidence of substantial 
shared genetic influences across general risk tolerance and risky behaviors: 72 of the 124 general 
risk tolerance loci contain a lead SNP for at least one of our other GWAS, and general risk 
tolerance is moderately to strongly genetically correlated (!"̂$! ~ 0.25 to 0.50) with a range of risky 
behaviors. Bioinformatics analyses imply that genes near general-risk-tolerance-associated SNPs 
are highly expressed in brain tissues and point to a role for glutamatergic and GABAergic 
neurotransmission. We find no evidence of enrichment for genes previously hypothesized to relate 
to risk tolerance.  
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Main text: 
Choices in important domains of life, including health, fertility, finance, employment, and social 
relationships, rarely have consequences that can be anticipated perfectly. The degree of variability 
in possible outcomes is called risk. Risk tolerance—defined as the willingness to take risks, 
typically to obtain some reward—varies substantially across humans and has been actively studied 
in the behavioral and social sciences. An individual’s risk tolerance may vary across domains, but 
survey-based measures of general risk tolerance (e.g., “Would you describe yourself as someone 
who takes risks?”) have been found to be good all-around predictors of risky behaviors such as 
portfolio allocation, occupational choice, smoking, drinking alcohol, and starting one’s own 
business1–3.  
Twin studies have established that various measures of risk tolerance are moderately heritable 
(ℎ&~30%, although estimates in the literature vary3–5). Discovery of specific genetic variants 
associated with general risk tolerance could advance our understanding of how genetic influences 
are amplified and dampened by environmental factors; provide insights into underlying biological 
pathways; enable the construction of polygenic scores (indexes of many genetic variants) that can 
be used as overall measures of genetic influences on individuals; and help distinguish genetic 
variation associated with general versus domain-specific risk tolerance. 
Although risk tolerance has been one of the most studied phenotypes in social science genetics, 
most claims of positive findings have been based on small-sample candidate gene studies 
(Supplementary Table 11.1), whose limitations are now appreciated6. To date, only two loci 
associated with risk tolerance have been identified in genome-wide association studies (GWAS)7,8.  
Here, we report results from large-scale GWAS of self-reported general risk tolerance (our primary 
phenotype) and six supplementary phenotypes: “adventurousness” (defined as the self-reported 
tendency to be adventurous vs. cautious); four risky behaviors: “automobile speeding propensity” 
(the tendency to drive faster than the speed limit), “drinks per week” (the average number of 
alcoholic drinks consumed per week), “ever smoker” (whether one has ever been a smoker), and 
“number of sexual partners” (the lifetime number of sexual partners); and the first principal 
component (PC) of these four risky behaviors, which we interpret as capturing the general 
tendency to take risks across domains. All seven phenotypes are coded such that higher phenotype 
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values are associated with higher risk tolerance or risk taking. Table 1 lists, for each GWAS, the 
datasets we analyzed and the GWAS sample size.   
 
Association analyses 
All seven GWAS were performed in European-ancestry subjects, following procedures described 
in a pre-specified analysis plan (https://osf.io/cjx9m/) and in Supplementary Information section 
2. 
In the discovery phase of our GWAS of general risk tolerance (n = 939,908), we performed a 
sample-size-weighted meta-analysis of results from the UK Biobank (UKB, n = 431,126) and a 
sample of research participants from 23andMe (n = 508,782). The UKB measure of general risk 
tolerance is based on the question: “Would you describe yourself as someone who takes risks? Yes 
/ No.” The 23andMe measure is based on a question about overall comfort taking risks, with five 
response options ranging from “very comfortable” to “very uncomfortable.” The genetic 
correlation9 between the UKB and 23andMe cohorts ("̂$ = 0.77, SE = 0.02) is smaller than one but 
high enough to justify our approach of pooling the two cohorts10.  
The Q-Q plot (Extended Data Fig. 3.2a) from the discovery GWAS exhibits substantial inflation 
(λGC = 1.41). According to the estimated intercept from a linkage disequilibrium (LD) Score 
regression11, only a small share of this inflation (~5%) in test statistics is due to bias. To account 
for this bias, we inflated GWAS standard errors by the square root of the LD Score regression 
intercept. 
We identified 124 approximately independent SNPs (pairwise r2 < 0.1) that attained genome-wide 
significance (P < 5´10-8). These 124 “lead SNPs” are listed in Supplementary Table 3.1 and 
shown in Fig. 1a. All have coefficients of determination (R2’s) below 0.02%, and the SNP with 
the largest per-allele effect is estimated to increase general risk tolerance by ~0.026 standard 
deviations in our discovery sample (Extended Data Fig. 3.3). 
In the replication phase of our GWAS of general risk tolerance (combined n = 35,445), we meta-
analyzed summary statistics from ten smaller cohorts. Additional details on cohort-level phenotype 
measures are provided in Supplementary Table 1.2. The questions differ in terms of their exact 
wording and number of response categories, but all questions ask subjects about their overall or 
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general attitudes toward risk. The genetic correlation9 between the discovery and replication 
GWAS is 0.83 (SE = 0.13). 123 of the 124 lead SNPs were available or well proxied by an available 
SNP in the replication GWAS results. Out of the 123 SNPs, 94 have a concordant sign (P = 1.7×10-
9) and 23 are significant at the 5% level in one-tailed t tests (P = 4.5×10-8) (Extended Data Fig. 
5.1). This empirical replication record matches theoretical projections that take into account 
sampling variation and the winner’s curse (Supplementary Information section 5).  
Our six supplementary GWAS—of adventurousness, four risky behaviors, and their principal 
component (n = 315,894 to 557,923; Supplementary Tables 1.1-1.2)—were conducted using 
methods comparable to those in the primary GWAS, but without a replication phase. Extended 
Data Fig. 3.2 (c to h) shows Q-Q plots and Extended Data Fig. 3.1 (a to f) shows Manhattan 
plots. 
Table 1 provides a summary overview of the seven GWAS. We identified a total of 865 lead SNPs 
across the seven GWAS. The lead SNPs are located in 611 approximately independent loci, where 
a locus is defined as the set of all SNPs in weak LD (pairwise r2 > 0.1) with a lead SNP. The SNP 
heritabilities of the seven phenotypes range from ~0.05 (for general risk tolerance) to ~0.16 (for 
the first PC of the four risky behaviors). 
 
Genetic overlap  
There is substantial overlap across the results of our GWAS. For example, 72 of the 124 general-
risk-tolerance lead SNPs are in loci that also contain lead SNPs for at least one of the other GWAS, 
including 45 for adventurousness and 49 for at least one of the four risky behaviors or their first 
PC. To empirically assess if this overlap could be attributed to chance, we conducted a resampling 
exercise under the null hypothesis that the lead SNPs of our supplementary GWAS are distributed 
independently of the 124 general-risk-tolerance lead loci. We strongly rejected this null hypothesis 
(P < 0.0001; Supplementary Information section 3.3.3). 
Several regions of the genome stand out for being associated both with general risk tolerance and 
with all or most of the supplementary phenotypes. We tested whether the signs of the lead SNPs 
located in these regions tend to be concordant across our primary and supplementary GWAS. We 
strongly rejected the null hypothesis of no concordance (P < 3×10-30; Supplementary 
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Information section 3.2.3), suggesting that these regions represent shared genetic influences, 
rather than colocalization of causal SNPs. Fig. 1b and Extended Data Fig. 3.4 show local 
Manhattan plots for some of these regions. The long-range LD region12 on chromosome 3 (~83.4 
to 86.9 Mb) contains lead SNPs from all seven GWAS as well as the most significant lead SNP 
from the general risk tolerance GWAS, rs993137 (P = 2.14×10–40), which is located in the gene 
CADM2. Another long-range LD region, on chromosome 6 (~25.3 to 33.4 Mb), covers the HLA-
complex and contains lead SNPs from all GWAS except drinks per week. Three candidate 
inversions (i.e., genomic regions that are highly prone to inversion polymorphisms; 
Supplementary Information section 2.9.2) on chromosomes 7 (~124.6 to 132.7 Mb), 8 (~7.89 
to 11.8 Mb), and 18 (~49.1 to 55.5 Mb) contain lead SNPs from six, five, and all seven of our 
GWAS, respectively. Finally, four other LD blocks13 that do not overlap known long-range LD or 
candidate inversion regions each contain lead SNPs from five of our GWAS (including general 
risk tolerance). The two long-range LD regions and the three candidate inversions have previously 
been found to be associated with numerous phenotypes, including many cognitive and 
neuropsychiatric phenotypes14.  
To investigate genetic overlap at the genome-wide level, we estimated genetic correlations with 
self-reported general risk tolerance using bivariate LD Score regression9. (For this and all 
subsequent analyses involving general risk tolerance, we used the summary statistics from the 
combined meta-analysis of our discovery and replication GWAS.) The estimated genetic 
correlations with our six supplementary phenotypes are all positive, larger than ~0.25, and highly 
significant (P < 2.3×10–30; Fig. 2), indicating that SNPs associated with higher general risk 
tolerance also tend to be associated with riskier behavior. The largest estimated genetic 
correlations are with adventurousness ("̂$ = 0.83, SE = 0.01), number of sexual partners (0.52, SE 
= 0.02), automobile speeding propensity (0.45, SE = 0.02), and the first PC of the four risky 
behaviors (0.50, SE = 0.02). 
Our estimates of the genetic correlations between general risk tolerance and the supplementary 
risky behaviors are substantially higher than the corresponding phenotypic correlations 
(Supplementary Tables 1.3 and 7.1). Although measurement error partly accounts for the low 
phenotypic correlations, the genetic correlations remain considerably higher even after adjustment 
of the phenotypic correlations for measurement error. The comparatively large genetic correlations 
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support the view that a general factor of risk tolerance partly accounts for cross-domain variation 
in risky behavior15,16 and imply that this factor is genetically influenced. The lower phenotypic 
correlations suggest that environmental factors are more important contributors to domain-specific 
risky behavior17,18. 
To increase the precision of our estimates of the SNPs’ effects on general risk tolerance, we 
leveraged the high degree of genetic overlap across our phenotypes by conducting Multi-Trait 
Analysis of GWAS (MTAG)19. We used as inputs the summary statistics of our GWAS of general 
risk tolerance, of our first five supplementary GWAS (i.e., not including the first PC of the four 
risky behaviors), and of a previously published GWAS on lifetime cannabis use20 (Supplementary 
Information section 9). MTAG increased the number of general-risk-tolerance lead SNPs from 
124 to 312 (Extended Data Fig. 9.1, Supplementary Table 9.1). 
We also estimated genetic correlations between general risk tolerance and 28 additional 
phenotypes (Fig. 2 and in Supplementary Table 7.1). These included phenotypes for which we 
could obtain summary statistics from previous GWAS, as well as five phenotypes for which we 
conducted new GWAS. The estimated genetic correlations for the personality traits extraversion 
("̂$ = 0.51, SE = 0.03), neuroticism (-0.42, SE = 0.04), and openness to experience (0.33, SE = 
0.03) are substantially larger in magnitude than previously reported phenotypic correlations21, 
pointing to substantial shared genetic influences among general risk tolerance and these traits. 
After Bonferroni correction, we also find significant positive genetic correlations with the 
neuropsychiatric phenotypes ADHD, bipolar disorder, and schizophrenia. Viewed in light of the 
genetic correlations we find with risky behaviors classified as externalizing (e.g., substance use, 
elevated sexual behavior, and fast driving), these results suggest the hypothesis that the overlap 
with the neuropsychiatric phenotypes is driven by their externalizing component. 
 
Biological annotation 
To gain insights into the biological mechanisms through which genetic variation influences general 
risk tolerance, we conducted a number of analyses. First, we systematically reviewed the literature 
that aimed to link risk tolerance to biological pathways (Supplementary Information section 11). 
Our review covered studies based on candidate genes (i.e., specific genetic variants used as proxies 
for biological pathways), pharmacological manipulations, biochemical assays, genetic 
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manipulations in rodents, as well as other research designs. Our review identified 132 articles that 
matched our search criteria (Supplementary Table 11.1).  
Previous work has focused on five main biological pathways: the steroid hormone cortisol, the 
monoamines dopamine and serotonin, and the steroid sex hormones estrogen and testosterone. 
Using a MAGMA22 competitive gene-set analysis, we found no evidence that SNPs within genes 
associated with these five pathways tend to be more associated with general risk tolerance than 
SNPs in other genes (Supplementary Table 11.3). Further, none of the other bioinformatics 
analyses we report below point to these pathways.  
We also examined the 15 most commonly tested autosomal genes within the dopamine and 
serotonin pathways, which were the focus of most of the 34 candidate-gene studies identified by 
our literature review. We verified that the SNPs available in our GWAS results tag most of the 
genetic variants typically used to test the 15 genes. Across one SNP-based test and two gene-based 
tests, we found no evidence of non-negligible associations between those genes and general risk 
tolerance (Fig. 1c and Supplementary Table 11.4). (We note, however, that some brain regions 
identified in analyses we report below are areas where dopamine and serotonin play important 
roles.) 
Second, we performed a MAGMA22 gene analysis to test each of ~18,000 protein-coding genes 
for association with general risk tolerance (Supplementary Information section 12.2). After 
Bonferroni correction, 285 genes were significant (Extended Data Fig. 12.1 and Supplementary 
Table 12.3). To gain insight into the functions and expression patterns of these 285 genes, we 
looked up these genes in the Gene Network23 co-expression database. Third, to identify relevant 
biological pathways and identify tissues in which genes near general-risk-tolerance-associated 
SNPs are expressed, we applied the software tool DEPICT24 to the SNPs with P values less than 
10-5 in our GWAS of general risk tolerance (Supplementary Information section 12.4).  
Both the Gene Network and the DEPICT analyses separately point to a role for glutamate and 
GABA neurotransmitters, which are the main excitatory and inhibitory neurotransmitters in the 
brain, respectively25 (Fig. 3a and Supplementary Tables 12.4 and 12.8). To our knowledge, no 
published large-scale GWAS of cognition, personality, or neuropsychiatric phenotypes has pointed 
to clear roles both for glutamate and GABA (although glutamatergic neurotransmission has been 
implicated in recent GWAS of schizophrenia26 and major depression27). Our results suggest that 
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the balance between excitatory and inhibitory neurotransmission may contribute to variation in 
general risk tolerance across individuals. 
The Gene Network and the DEPICT tissue enrichment analyses also both separately point to 
enrichment of the prefrontal cortex and the basal ganglia (Fig. 3b and Supplementary Tables 
12.4, 12.6, and 12.7). The cortical and subcortical regions highlighted by DEPICT include some 
of the major components of the cortical-basal ganglia circuit, which is known as the reward system 
in human and non-human primates and is critically involved in learning, motivation, and decision-
making, notably under risk and uncertainty28,29. We caution, however, that our results do not point 
exclusively to the reward system.  
Lastly, we used stratified LD Score regression30 to test for the enrichment of SNPs associated with 
histone marks in 10 tissue or cell types (Supplementary Information section 12.1). Central 
nervous system tissues are the most enriched, accounting for 44% (SE = 3%) of the heritability 
while comprising only 15% of the SNPs (Extended Data Fig. 12.3a and Supplementary Table 
12.2). Immune/hematopoietic tissues are also significantly enriched. While a role for the immune 
system in modulating risk tolerance is plausible given prior evidence of its involvement in several 
neuropsychiatric disorders26,27, future work is needed to confirm this result and to uncover specific 
pathways that might be involved.  
 
Polygenic prediction  
We constructed polygenic scores of general risk tolerance to gauge their potential usefulness in 
empirical research (Supplementary Information section 10). We used the Add Health, HRS, 
NTR, STR, UKB-siblings, and Zurich cohorts as validation cohorts (Supplementary Table 1.1 
provides an overview of these cohorts; the UKB-siblings cohort comprised individuals with at 
least one full sibling in the UKB). For each validation cohort, we constructed the score using 
summary statistics from a meta-analysis of our discovery and replication GWAS that excluded the 
cohort. Our measure of predictive power is the incremental R2 (or pseudo-R2) from adding the 
score to a regression of the phenotype on sex, birth year, and the top ten principal components of 
the genetic relatedness matrix.  
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Our preferred score was constructed with LDpred31. In the UKB-siblings cohort, which is our 
largest validation cohort (+	~ 35,000), the score’s predictive power is 1.6% for general risk 
tolerance, 1.0% for the first PC of the four risky behaviors, 0.8% for number of sexual partners, 
0.6% for automobile speeding propensity, and ~0.15% for drinks per week and ever smoker. 
Across our validation cohorts, the score is also predictive of several personality phenotypes and a 
suite of real-world measures of risky behaviors in the health, financial, career, and other domains 
(Extended Data Figs. 10.1-10.2 and Supplementary Tables 10.1-10.3). The incremental R2 we 
observe for general risk tolerance is consistent with the theoretical prediction, given the SNP 
heritability of general risk tolerance (Table 1) and the imperfect genetic correlations across the 
GWAS and validation cohorts32,33 (Supplementary Information section 10.4). 
 
Discussion 
Our results provide insights into biological mechanisms that influence general risk tolerance. Our 
bioinformatics analyses point to the role of gene expression in brain regions that have been 
identified by neuroscientific studies on decision-making, notably the prefrontal cortex, basal 
ganglia, and midbrain, thereby providing convergent evidence with that from neuroscience28,29. 
Yet our analyses failed to find evidence for the main biological pathways that had been previously 
hypothesized to influence risk tolerance. Instead, our analyses implicate genes involved in 
glutamatergic and GABAergic neurotransmission, which were heretofore not generally believed 
to play a role in risk tolerance. 
Although our focus has been on the genetics of general risk tolerance and risky behaviors, 
environmental and demographic factors account for a substantial share of these phenotypes’ 
variation. We observe sizeable effects of sex and age on general risk tolerance in the UKB data 
(Extended Data Fig. 1.1), and life experiences have been shown to affect both measured risk 
tolerance and risky behaviors (e.g., refs. 34,35). The data we have generated will allow researchers 
to construct and use polygenic scores of general risk tolerance to measure how environmental, 
demographic, and genetic factors interact with one another. 
For the behavioral sciences, our results bear on the ongoing debate about the extent to which risk 
tolerance is a “domain-general” as opposed to a “domain-specific” trait. Low phenotypic 
correlations in risk tolerance across decision-making domains have been interpreted as supporting 
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the domain-specific view17,18. Across the risky behaviors we study, we find that the genetic 
correlations are considerably higher than the phenotypic correlations (even after the latter are 
corrected for measurement error) and that many lead SNPs are shared across our phenotypes. 
These observations suggest that the low phenotypic correlations across domains are due to 
environmental factors that dilute the effects of a genetically-influenced domain-general factor of 
risk tolerance.  
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a  
 
b  c   
Figure 1 | Manhattan plots. In all panels, the x-axis is chromosomal position; the y-axis is the 
significance on a −log10 scale; the horizontal dashed line marks the threshold for genome-wide 
significance (P = 5×10−8); and each approximately independent (pairwise r2 < 0.1) genome-wide 
significant association (“lead SNP”) is marked by a red ×. a, Manhattan plots for the discovery 
GWAS of general risk tolerance. b, Local Manhattan plots of two genomic regions that contain 
lead SNPs for all seven of our GWAS. The gray background marks the locations of long-range LD 
or candidate inversion regions. c, Local Manhattan plots of the loci around the 15 most commonly 
tested candidate genes in the prior literature on the genetics of risk tolerance. Each locus comprises 
all SNPs within 500 kb of the gene’s borders that are in LD	("& > 0.1) with a SNP in the gene.  
The 15 plots are concatenated and shown together in the panel, divided by the black vertical lines. 
The 15 genes are not particularly strongly associated with general risk tolerance or the risky 
behaviors, as can be seen by comparing the results within each row across panels b and c (the three 
rows correspond to the GWAS of general risk tolerance, adventurousness, and the first PC of the 
four risky behaviors).  
 
 
 17 
 
Figure 2 | Genetic correlations with general risk tolerance. The genetic correlations were 
estimated using bivariate LD Score (LDSC) regression9. Error bars show 95% confidence 
intervals. For the supplementary phenotypes and the additional risky behaviors, green bars 
represent significant estimates with the expected signs, where higher risk tolerance is associated 
with riskier behavior. For the other phenotypes, blue bars represent significant estimates. Light 
green and light blue bars represent genetic correlations that are statistically significant at the 5% 
level, and dark green and dark blue bars represent correlations that are statistically significant after 
Bonferroni correction for 34 tests (the total number of phenotypes tested). Grey bars represent 
correlations that are not statistically significant at the 5% level. 
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Figure 3 | Results from selected biological analyses. a, DEPICT gene-set enrichment diagram. 
We identified 93 reconstituted gene sets that are significantly enriched (FDR < 0.01) for genes 
overlapping loci associated with general risk tolerance; using the Affinity Propagation method36, 
these were grouped into the 13 clusters displayed in the graph. Each cluster was named after the 
most significant gene set it contained, and each cluster’s color represents the permutation P value 
of its most significant gene set. The “synapse part” cluster includes the gene set “glutamate 
receptor activity,” and several members of the “GABAA receptor activation” cluster are defined 
by gamma-aminobutyric acid signaling. Overlap between the named representatives of two 
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clusters is represented by an edge. Edge width represents the Pearson correlation ρ between the 
two respective vectors of gene membership scores (ρ < 0.3, no edge; 0.3 ≤ ρ < 0.5, thin edge; 0.5 
≤ ρ < 0.7, intermediate edge; ρ ≥ 0.7, thick edge). b, Results of DEPICT tissue enrichment analysis 
using GTEx data. The panel shows whether the genes overlapping loci associated with general risk 
tolerance are significantly overexpressed (relative to genes in random sets of loci matched by gene 
density) in various tissues. Tissues are grouped by organ or tissue type. The orange bars correspond 
to tissues with significant overexpression (FDR < 0.01). The y-axis is the significance on a −log10 
scale. 
 
  
Table 1 | GWAS results  
 
GWAS Cohorts analyzed n Mean !" LD Score intercept (SE) # lead SNPs SNP h2 (SE) 
General risk tolerance (disc. GWAS) UKB; 23andMe 939,908 1.85 1.04 (0.01) 124 0.046 (0.001) 
General risk tolerance (rep. GWAS) 10 indep. cohorts 35,445 1.03 1.00 (0.07) 0 -- 
General risk tolerance (disc. + rep.) UKB; 23andMe; 10 indep. cohorts 975,353 1.87 1.04 (0.01) 132 0.045 (0.001) 
Adventurousness 23andMe 557,923 1.98 1.05 (0.01) 167 0.098 (0.002) 
Automobile speeding propensity UKB 404,291 1.53 1.03 (0.01) 42 0.079 (0.003) 
Drinks per week UKB 414,343 1.61 1.03 (0.01) 85 0.085 (0.003) 
Ever smoker UKB; TAG Consortium 37 518,633 1.97 1.05 (0.01) 223 0.109 (0.003) 
Number of sexual partners UKB 370,711 1.77 1.04 (0.01) 118 0.128 (0.003) 
First PC of the four risky behaviors UKB 315,894 1.77 1.05 (0.01) 106 0.156 (0.004) 
The table provides an overview of the GWAS of our primary and supplementary phenotypes. “n”: GWAS sample size; “Mean !"”: 
mean GWAS chi-squared statistics across HapMap3 SNPs with minor allele frequency (MAF) greater than 0.01; “LD Score intercept”: 
estimate of the intercept from a LD Score regression11 using HapMap3 SNPs with MAF greater than 0.01; “# lead SNPs”: number of 
lead SNPs, calculated after the associated statistics have been adjusted using the estimated LD score intercept; “SNP h2”: SNP heritability 
estimated with the Heritability Estimator from Summary Statistics (HESS) method38 using 1000 Genomes phase 3 SNPs with MAF 
greater than 0.05; “disc.”: discovery; “rep.”: replication; “indep.”: independent.  
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